A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML

**Disease Area:** Leukemia, Acute Myeloid (AML)

**Investigator:** Colleen Delaney

**Institution:** Nohla Therapeutics Inc

**CIRM Grant:** CLIN2-09574 (Closed)

**Award Value:** $4,310,000

**Trial Sponsor:** Nohla Therapeutics Inc

**Trial Stage:** Phase 2

**Trial Status:** Closed

**Targeted Enrollment:** 146

**ClinicalTrials.gov ID:** NCT03301597

**Details:**
Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.

**Design:**
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.

**Goal:**
evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.

**News about this clinical trial:**
Nohla Therapeutics Awarded $6.9 Million Grant From The California Institute for Regenerative Medicine
Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML

Contact Trial Sponsor